6.5 C
New York
Monday, August 2, 2021

Popular antibiotic against COVID-19 turned out to be useless – says new study

Must Read

Aakash Molpariya
Aakash started in Nov 2018 as a writer at Revyuh.com. Since joining, as writer, he is mainly responsible for Software, Science, programming, system administration and the Technology ecosystem, but due to his versatility he is used for everything possible. He writes about topics ranging from AI to hardware to games, stands in front of and behind the camera, creates creative product images and much more. He is a trained IT systems engineer and has studied computer science. By the way, he is enthusiastic about his own small projects in game development, hardware-handicraft, digital art, gaming and music. Email: aakash (at) revyuh (dot) com

Treating coronavirus infection with azithromycin doesn’t seem to make sense, new research says.

The antibiotic azithromycin, which is prescribed to patients with coronavirus, does not improve their condition. When treating COVID-19, it is better to completely abandon this drug until the bacteria become addicted to it.

Earlier, virologists from France stated that azithromycin helps in the treatment of coronavirus, and the combination of azithromycin and the antimalarial agent hydroxychloroquine significantly reduces the severity of COVID-19.

Scientists from the University of California at San Francisco with scientists from Stanford University conducted a study and found that the use of azithromycin by COVID patients did not reduce their risk of entering intensive care or death from infection.

“It is important that doctors around the world in the near future stop using this drug to fight COVID-19, which will reduce the risk that bacteria will begin to acquire resistance to its action,” American and British experts say.

They conducted a study involving 298 people who were diagnosed with the coronavirus.

Patients with mild to moderate forms of the disease taking high doses of azithromycin did not improve their condition.

In severely ill patients, the antibiotic did not reduce their likelihood of being admitted to intensive care.

These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection

the scientists concluded.

Most of the trials done so far with azithromycin have focused on hospitalized patients with pretty severe disease.

Our paper is one of the first placebo-controlled studies showing no role for azithromycin in outpatients.

Photo by Dimitar DILKOFF / AFP) (Photo by DIMITAR DILKOFF/AFP via Getty Images

- Advertisement -
- Advertisement -

Latest News

This much coffee raises your risk of dementia

While a quick coffee may perk us up, new research from the University of South Australia shows that too...
- Advertisement -

More Articles Like This

- Advertisement -